Vertex Pharmaceuticals has current Real Value of $192.05 per share. The regular price of the company is $177.55. At this time the company appears to be undervalued. This module measures value of Vertex Pharmaceuticals from inspecting the company fundamentals such as Shares Outstanding of 257.04M, Return On Equity of
56.25% and Operating Margin of 29.00% as well as reviewing its technical indicators and Probability Of Bankruptcy. In general, we recommend to buy undervalued stocks and to dispose of overvalued stocks since at some point securities prices and their ongoing real values will draw towards each other.
September 16, 2019
Vertex Pharmaceuticals is very steady asset. Calculation of real value of Vertex Pharmaceuticals is based on 3 months time horizon. Increasing Vertex Pharmaceuticals time horizon generally increases accuracy of value calculation and significantly improves predictive power of the methodology used.
Valuation Drivers Correlation
|Click cells to compare fundamentals||View All Correlations|
Vertex Pharmaceuticals Market CapVertex Pharmaceuticals Incorpor is rated below average in market capitalization category among related companies. Market capitalization of Biotechnology industry is at this time estimated at about 192.4 Billion. Vertex Pharmaceuticals totals roughly 45.64 Billion in market capitalization claiming about 24% of stocks in Biotechnology industry.
|Horizon||30 Days Login to change|
Vertex Pharmaceuticals Incorpor is rated below average in price to sales category among related companies. It is rated below average in beta category among related companies totaling about 0.08 of Beta per Price to Sales. The ratio of Price to Sales to Beta for Vertex Pharmaceuticals Incorpor is roughly 12.58
|Price to Sales ( times )|